1. Home
  2. AFYA vs DBVT Comparison

AFYA vs DBVT Comparison

Compare AFYA & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Afya Limited

AFYA

Afya Limited

HOLD

Current Price

$13.42

Market Cap

1.4B

Sector

Real Estate

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$22.70

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AFYA
DBVT
Founded
1999
2002
Country
Brazil
France
Employees
N/A
90
Industry
Other Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.1B
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
AFYA
DBVT
Price
$13.42
$22.70
Analyst Decision
Hold
Buy
Analyst Count
5
7
Target Price
$17.00
$31.75
AVG Volume (30 Days)
90.3K
244.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
1.71%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,151,000.00
Revenue This Year
$14.67
$1,768.71
Revenue Next Year
$7.84
$1,028.88
P/E Ratio
$9.30
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.12
$3.82
52 Week High
$19.76
$26.19

Technical Indicators

Market Signals
Indicator
AFYA
DBVT
Relative Strength Index (RSI) 31.69 58.09
Support Level N/A $20.11
Resistance Level $15.35 $25.52
Average True Range (ATR) 0.40 1.38
MACD -0.12 -0.04
Stochastic Oscillator 10.95 69.51

Price Performance

Historical Comparison
AFYA
DBVT

About AFYA Afya Limited

Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: